Rami Manochakian: Results of TROPION/Lung05 Phase 2 trial are out
Rami Manochakian shared a post on X:
“Hot off the press.
Just published in the Journal of Clinical Oncology.
Results of TROPION/Lung05 Phase 2 trial of Datopotamab Deruxtecan in:
Advanced Non–Small Cell Lung Cancer with Actionable Genomic Alterations with progression after Targeted Therapy and Chemotherapy.
Response Rate:
- Overall: 36 percent
- In EGFR+: 44 percent
- In ALK+: 24 percent
Overall DCR: 79 percent.”
Authors: Jacob Sands, Myung-Ju Ahn, Aaron Lisberg, Byoung Chul Cho, George Blumenschein Jr, Elaine Shum, Elvire Pons Tostivint, Yasushi Goto, Kiyotaka Yoh, Rebecca Heist, Junichi Shimizu, Jong-Seok Lee, Paul Baas, David Planchard, Maurice Pérol, Enriqueta Felip, Wu-Chou Su, MD, Hong Zebger-Gong, Lan Lan, Chelsea Liu, Paul Howarth, Rachel Chiaverelli, Luis Paz-Ares.”
Rami Manochakian is a thoracic medical oncologist at Mayo Clinic, Florida. He specializes in thoracic malignancies, including lung cancer, mesothelioma, and thymic tumors, he has dedicated his career to advancing the field of oncology. He is also recognized as a leader in medical education, serving in various educational roles at Mayo Clinic and national and international medical societies, including ASCO, ALA, and IASLC.
More posts featuring Rami Manochakian.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023